There was no significant difference among the number of ER-positive, HER2-positive or triple-negative breast cancer (TNBC) cases among the three sub-populations, although slightly more TNBC cases were among the sub-population III (27%) (OR2W3 upregulation) patients compared to sub-populations I and II (25% and 23%) (OR2B6 and OR2T8 upregulation) (Fig. S3A). The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.